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Combined Metabolic Activators Accelerates Recovery in
Mild-to-Moderate COVID-19
Ozlem Altay, Muhammad Arif, Xiangyu Li, Hong Yang, Mehtap Aydın, Gizem Alkurt,
Woonghee Kim, Dogukan Akyol, Cheng Zhang, Gizem Dinler-Doganay, Hasan Turkez,
Saeed Shoaie, Jens Nielsen, Jan Borén, Oktay Olmuscelik, Levent Doganay,
Mathias Uhlén, and Adil Mardinoglu*
COVID-19 is associated with mitochondrial dysfunction and metabolic
abnormalities, including the deficiencies in nicotinamide adenine dinucleotide
(NAD+) and glutathione metabolism. Here it is investigated if administration
of a mixture of combined metabolic activators (CMAs) consisting of
glutathione and NAD+ precursors can restore metabolic function and thus
aid the recovery of COVID-19 patients. CMAs include l-serine,
N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate, salt form
of l-carnitine. Placebo-controlled, open-label phase 2 study and
double-blinded phase 3 clinical trials are conducted to investigate the time of
symptom-free recovery on ambulatory patients using CMAs. The results of
both studies show that the time to complete recovery is significantly shorter
in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials
compared to placebo group. A comprehensive analysis of the plasma
metabolome and proteome reveals major metabolic changes. Plasma levels of
proteins and metabolites associated with inflammation and antioxidant
metabolism are significantly improved in patients treated with CMAs as
compared to placebo. The results show that treating patients infected with
COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting
a role for such a therapeutic regime in the treatment of infections leading to
respiratory problems.
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1. Introduction
Many patients infected with COVID-19 suf-
fer from respiratory problems, metabolic
dysfunction and exacerbated inflamma-
tion that triggers organ failure.[1] This
has led to more than 3 million COVID-
19 related deaths globally[2] due to severe
outcomes.[3–7] Although new treatments
regimes have been introduced,[8,9] includ-
ing Remdesivir and Favipiravir (FP),[10,11]
there is a need to complement existing ther-
apeutic interventions with new approaches,
in particular those targeting mitochondrial
dysfunction and metabolic abnormalities. A
potential approach is to promote metabolic
functions by metabolic activators.
Metabolic abnormalities and a hyperin-
flammatory response are associated with
the deficiencies in nicotinamide adenine
dinucleotide (NAD+) and glutathione
(GSH) metabolism.[12,13] The cellular de-
pletion of NAD+ and GSH may be primary
factors related to the COVID-19 and the
risk for mortality. Given the lack of targeted
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treatments for emerging viruses, the antiviral properties of re-
purposed drugs and the use of dietary supplements have gained
considerable attention. N-acetyl-l-cysteine (NAC), nicotinamide
riboside (NR), and l-carnitine have been tested in human tri-
als of viral diseases including COVID-19, and serine has been
evaluated in the treatment of immune system-related disorders
(Table S1, Supporting Information). Serine is an essential
metabolite for modulation of adaptive immunity by supporting
the effector T-cell responses.[14] Many studies have shown that
these metabolic activators are beneficial in treating lung diseases
and viral infectious diseases.[15–24] Their pharmacological prop-
erties, side effects, and dosing regimens are known, which are
advantageous for rapid testing in clinical trials and COVID-19
treatment protocols.[24,25]
Previously, we found that combined metabolic activators
(CMA) consisting of l-serine (serine), NAC, NR, and l-carnitine
tartrate (LCAT, the salt form of l-carnitine) is a potential treat-
ment for nonalcoholic fatty liver disease based on integrative
analysis of multi-omics data derived from different metabolic
conditions.[24,26–28] We subsequently demonstrated the safety
of CMA in animals and humans.[29] That study also revealed
that CMA significantly improves plasma levels of metabo-
lites associated with antioxidant metabolism and inflammatory
proteins.[29]
We therefore hypothesized that administration of CMA would
improve metabolic conditions associated with COVID-19, in-
crease the level of NAD+ and GSH, activate the mitochondrial
metabolism in liver and other tissues, and potentially accelerate
the recovery of COVID-19 patients or reduce its severity. To test
this hypothesis, we conducted a randomized, controlled, open-
label, placebo-controlled phase-2 study to evaluate the efficacy,
tolerability, and safety of CMA in ambulatory COVID-19 patients.
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We have also generated proteomics and metabolomics data for
detailed characterization of the patients recruited in the phase 2
study and revealed the underlying molecular mechanisms associ-
ated with the improved patient phenotype. Based on the favorable
findings from the phase-2 study, we conducted a randomized,
controlled, double-blinded phase-3 study to evaluate the efficacy,
tolerability, and safety of CMA in ambulatory COVID-19 patients.
Here, we report the results from the phase-2 and phase-3 clinical
trial, including the effect on the time to recovery which was the
primary endpoint for both studies. The results are complimented
with an extensive analysis of a large number of biochemical pa-
rameters, based on both protein and metabolite analysis.
2. Results
2.1. CMA Accelerates Recovery of COVID-19 Patients in
Open-Label Phase-2 Clinical Trial
In the phase-2 study, we recruited 100 adults with a confirmed
positive PCR test for COVID-19. Five patients dropped out for
personal reasons, and two were hospitalized before administrat-
ing the CMA. Of the 93 remaining patients, all of whom com-
pleted the study, 71 were randomly assigned to the CMA group
and 22 to the placebo group (Figure 1A, Dataset S1A, Supporting
Information); all patients also received standard of care therapy
(for Turkey) with hydroxychloroquine (HQ) for five d. On Days 0
and 14, we assessed the clinical variables and analyzed the differ-
ences between Day 0 and Day 14 in the CMA and placebo groups
(Dataset S2A, Supporting Information).
The patients’ mean age participated in the phase-2 study was
35.6 years (19–66 years), and 60% were men (Table S2, Support-
ing Information). Patients had a low prevalence of coexisting con-
ditions such as hypertension (2.1%) and type 2 diabetes mellitus
(5.3%), and the mean body mass index (BMI) was 24.8 (16.8–
37.8). The most common COVID-19 symptoms were tiredness
(51.6%), headache (48.3%), cough (31.1%), muscle or joint pain
(60.2%), smell or taste disorder (26.8%), sore throat (23.6%), fever
(20.4%), breathing issues (6.4%), nausea or vomiting (5.3%), and
diarrhea (2.1%). The baseline demographic and clinical charac-
teristics were similar in the CMA and placebo groups (Table S2,
Datasets S1A and S2A, Supporting Information). All patients
who fully recovered had a negative PCR test for COVID-19 on Day
14. With regards to safety, no severe adverse events occurred and
two patients in the CMA group (2.8%) reported adverse events.
Both had a mild rash on the upper body and decided to complete
the study (Dataset S1A, Supporting Information). Adverse effects
were uncommon and self-limiting.
In the phase-2 study, we observed that the mean recovery time
(the primary outcome variable) was shorter in the CMA group
than in the placebo group (6.6 vs 9.3 d, p = 0.0001) (Figure 1B).
A univariate Cox regression analysis shows that CMA was sig-
nificantly associated with recovery time (p < 0.0004, hazard ratio
2.59, 95% confidence interval 1.54–4.38) (Table S3, Supporting
Information). Multivariate Cox regression analysis analyses also
confirmed that CMA independently reduced recovery time after
adjustment for age, gender, other treatment histories, smoking,
and alcohol consumption (p< 0.0004, hazard ratio 2.68, 95% con-
fidence interval 1.57–4.59) (Figure 1C).
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Figure 1. The effect of CMA on the symptoms of COVID-19 patients in phase-2 clinical trial. A) The effect of the CMA in 93 COVID-19 patients is tested
in a randomized, controlled, open-label, placebo-controlled phase 2 clinical study. Study design for testing the effect of CMA is presented. B) Based on
Kaplan–Meier analysis, it is shown that CMA accelerates the recovery of the COVID-19 patients. Number of patients reporting COVID-19 symptoms are
reported in the Table S2 (Supporting Information). C) Multivariate Cox regression analysis of CMA treatment in phase-2 clinical trial.
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Figure 2. The effect of CMA on the symptoms of COVID-19 patients in phase-3 clinical trial. A) The effect of the CMA in 304 COVID-19 patients is tested
in a randomized, controlled, double-blinded, placebo-controlled phase 3 clinical study. Study design for testing the effect of CMA is presented. B) Based
on Kaplan–Meier analysis, it is shown that CMA accelerates the recovery of the COVID-19 patients. Number of patients reporting COVID-19 symptoms
are reported in the Table S2 (Supporting Information). C) Multivariate Cox regression analysis of CMA treatment in phase-3 clinical trial.
2.2. CMA Accelerates Recovery of COVID-19 Patients in
Double-Blinded Phase-3 Clinical Trial
In the phase-3 study, we recruited and randomly assigned 309
adult patients with a confirmed positive PCR test for COVID-19.
Three patients dropped out for personal reasons, one patient in
the CMA group dropped due to mild allergy, and one patient in
the placebo group was hospitalized. Of the 304 remaining pa-
tients, all of whom completed the study, 229 were in the CMA
group and 75 in the placebo group (Figure 2A, Dataset S2B, Sup-
porting Information). 62 patients in the placebo group and 187
patients in the CMA group received standard therapy with HQ
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for 5 d. Meanwhile, 13 patients in the placebo group and 42 pa-
tients in the CMA group received standard therapy with FP for
5 d. On Days 0 and 14, we assessed the clinical variables and ana-
lyzed the differences between Day 0 and Day 14 in the CMA and
placebo groups (Dataset S2B, Supporting Information).
The mean age of the patients who participated in the phase-
3 study was 36.3 years (18–66 years), and 57.6% were men
(Table S2, Supporting Information). Patients had a low preva-
lence of coexisting conditions such as hypertension (9.2%)
and type 2 diabetes mellitus (6.2%), and the mean BMI was
26.7 (16.8–45.6). The most common symptoms were muscle or
joint pain (60.8%), tiredness (50.3%), cough (43.4%), headache
(38.1%), fever (28.2%), sore throat (24%), smell or taste disorder
(20.7%), breathing issues (9.2%), nausea or vomiting (7.8%), and
diarrhea (3.6%). The baseline demographic and clinical charac-
teristics were similar in the CMA and placebo groups (Table S2,
Dataset S1B, Supporting Information). Two patients in the CMA
group (0.6%) reported mild rash and skin redness as adverse
events, and both decided to complete the study (Dataset S1B, Sup-
porting Information).
In the phase-3 study, we observed that the mean recovery time
was shorter in the CMA group than in the placebo group (5.7 vs
9.2 d, p<0.0001) (Figure 2B). A univariate Cox regression anal-
ysis shows that CMA was significantly associated with recov-
ery time (p < 2.0e-16, hazard ratio 5.63, 95% confidence inter-
val 4.11–7.71) (Table S4, Supporting Information). Multivariate
Cox regression analysis also confirmed that CMA independently
reduced recovery time after adjustment for HQ/FP treatment,
age, gender, other treatment histories, smoking, and alcohol con-
sumption (p < 2.0e-16, hazard ratio 5.77, 95% confidence interval
4.17–7.96) (Figure 2C).
To investigate if the administration of CMA is affected by the
standard therapy with HQ and FP, we calculated the mean recov-
ery time in the patient groups treated with HQ and FP separately.
We observed that the mean recovery time was again shorter in
CMA group than in placebo group (5.76 vs 9.32 d, p < 0.0001) in
the patients treated with HQ only (Figure S1A, Supporting Infor-
mation) and (5.54 vs 8.77 d, p = 0.00034) in the patients treated
with FP only (Figure S1B, Supporting Information). We also com-
pared the independent effect of the HQ and FP on COVID-19 pa-
tients and found that these two drugs had a similar efficacy on the
recovery of the patients in all (Figure S2A, Supporting Informa-
tion), placebo (Figure S2B, Supporting Information) and CMA
(Figure S2C, Supporting Information) patient groups. Hence, we
observed that CMA administration accelerated the recovery of the
COVID-19 patients independent of the standard therapy.
2.3. CMA Improves Clinical Health in All COVID-19 Patients
We measured clinical variables in all of the patients recruited
in the phase-2 and phase-3 studies and analyzed the differences
before and after the administration of CMA in the active and
placebo groups (Figure 3A). Analysis of secondary outcome vari-
ables showed that serum alanine aminotransferase (ALT) levels
were significantly (p = 0.032) lower on Day 14 versus Day 0 only
in the CMA group (Figure 3B). We found that the lactate dehy-
drogenase (LDH) levels (Figure 3C) and creatinine levels (Fig-
ure 3D) were significantly lower on Day 14 versus Day 0 only in
the CMA group (p = 2.88 E-04 and p = 3.07 E-09), respectively. In
contrast, we found that the plasma glucose level was significantly
increased on Day 14 versus Day 0 only in the placebo group (Fig-
ure 3E). Hence, we observed that the level of ALT, LDH, creatinine
and glucose was significantly improved due to the administration
of CMA.
We also measured the level of clinical chemistry parameters
and found that their levels are significantly changed in both
CMA and placebo groups. We found that the level of aspartate
aminotransferase (AST) (Figure S3A, Supporting Information)
and C-reactive protein (Figure S3B, Supporting Information)
were significantly lower in both CMA and placebo groups on
Day 14 versus Day 0. In contrast, we found that the levels of
platelets (Figure S3C, Supporting Information), white blood
cells (Figure S3D, Supporting Information), neutrophils (Fig-
ure S3E, Supporting Information), lymphocytes (Figure S3F,
Supporting Information), hemoglobin (Figure S4A, Supporting
Information), cholesterol (Figure S4B, Supporting Information),
and triglyceride (Figure S4C, Supporting Information) were
significantly increased in both CMA and placebo groups on Day
14 versus Day 0. We observed that these differences were due
to the recovery of the patients and not affected by the adminis-
tration of CMA. D-dimer and Ferritin levels did not significantly
differ between both groups on Day 14 versus Day 0 (p > 0.05;
Figure 3A, Dataset S2C, Supporting Information). Our analysis
suggested that administration of CMA improved the clinical
parameters in parallel to the decrease in the recovery time.
2.4. Metabolomic and Inflammatory Cytokine Analysis for
Characterization of COVID-19 Patients
We characterized the metabolome and inflammatory cytokine
markers of 93 COVID-19 patients involved in the phase-2 study
and revealed changes associated with the disease and adminis-
tration of CMA at the molecular level. We analyzed the plasma
level of metabolites and inflammatory protein markers on Day 0
and Day 14 in both groups. Generation of omics data may unveil
the underlying molecular mechanisms associated to the differ-
ences before and after the disease as well as the differences in the
placebo and CMA groups. We generated plasma metabolomics
data and analyzed the plasma levels of 1021 different metabo-
lites (Dataset S3, Supporting Information). After filtering out the
metabolites with missing values in more than 50% of samples,
the plasma metabolomics dataset included 928 metabolites that
were subjected to statistical analysis. Significant differences in
plasma metabolite levels on Day 14 versus Day 0 in both the CMA
and placebo groups (Dataset S4, Supporting Information) and be-
tween the groups on Day 14 and Day 0 (Dataset S5, Supporting
Information) are presented. We investigated the associations be-
tween the plasma level of all metabolites with the plasma levels
of the metabolic activators (Dataset S6, Supporting Information).
We also measured the plasma levels of 96 inflammatory pro-
tein markers using an inflammation panel to quantify the plasma
level of target proteins (Dataset S7, Supporting Information). Af-
ter quality control and exclusion of proteins with missing values
in more than 50% of samples, 72 proteins were analyzed. Signif-
icant differences in plasma protein levels between Day 14 versus
Day 0 in both CMA and placebo groups (Dataset S8, Supporting
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Figure 3. The effect of the CMA on clinical variables. A) Heatmap shows log2FC based alterations of the clinical variables, which are compared before and
after the administration of CMA in both active and placebo groups. Asterisks indicate statistical significance based on Student’s t-test. P value <0.05. The
level of clinical variables including B) ALT, C) LDH, D) creatinine, and E) glucose is presented in the CMA and placebo groups in all 397 patients involved
in Phase 2 and Phase 3 clinical trials. These clinical parameters are significantly improved due to the administration of CMA after 14 d. The decrease in
the recovery of the patients has been supported by the improvement in clinical variables and the metabolic health status of the patients.
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Information) and between the CMA and placebo groups on Day
14 and Day 0 (Dataset S9, Supporting Information) are pre-
sented. We investigated the associations between the plasma level
of all inflammation-related proteins with the plasma levels of
metabolic activators (Dataset S10, Supporting Information). The
results showed that the administration of CMA effected a large
number of biochemical parameters, based on both metabolomics
and proteomics analysis.
2.5. CMA Increases the Plasma Levels of Metabolites Associated
with Metabolic Activators
We first analyzed the plasma levels of serine, carnitine, NR, and
cysteine. CMA increased the plasma levels of each metabolic ac-
tivator proportionally on Day 14 versus Day 0 in the CMA group
(Figure 4A, Dataset S4, Supporting Information). Moreover, the
plasma levels of NR, nicotinamide, 1-methylnicotinamide and
N1-methyl-2-pyridone-5-carboxamide (associated with NR and
NAD+ metabolism); of serine and N-acetylglycine (associated
with serine and glycine metabolism); and of deoxycarnitine,
acetylcarnitine, (R)-3-hydroxybutyrylcarnitine, linoleoylcarnitine
(C18:2), and dihomo-linoleoylcarnitine (C20:2) (associated with
carnitine metabolism) were significantly higher in the CMA
group than in the placebo group on Day 14 (Dataset S5, Support-
ing Information).
Next, we investigated the relationship with the plasma level
of administrated CMAs and other metabolites (Dataset S6, Sup-
porting Information). We analyzed the 38 most significantly cor-
related plasma metabolites with serine, l-carnitine, NR, and cys-
teine (Figure 4B, Dataset S6, Supporting Information) and found
three clusters of metabolites which are significantly correlated
with serine only, cysteine only and significantly correlated with
all serine, l-carnitine, and NR. We observed that cysteine had a
different dynamic compared to the other three metabolic activa-
tors. On the other hand, homostachydrine involved in xenobiotics
metabolism as well as succinoyltaurine involved in methionine,
cysteine, SAM, and taurine metabolism were significantly nega-
tively correlated with serine and cysteine, respectively.
2.6. Cytokine Levels During Recovery of COVID-19 Patients
Mortality in COVID-19 patients has been strongly associated with
the presence of the cytokine storm induced by the virus. In-
creased cytokine levels are also linked with increased viral load
and the severe form of the disease.[30] To study the changes in
the cytokine levels, we determined the dynamic range of 72 in-
flammatory proteins in plasma samples with the Olink multi-
plex inflammation panel (Dataset S7, Supporting Information).
The plasma level of 14 proteins were significantly (false-discovery
rate: FDR<0.01) changed following the recovery of the patients
on Day 14 versus Day 0, in the placebo group (Figure 5A, Dataset
S8, Supporting Information). The plasma levels of nine pro-
teins including CSF-1, CX3CL1, CXCL10, IFN-gamma, IL-18R1,
MCP-2, OPG, TNF, and TRAIL were significantly (FDR<0.01) de-
creased, whereas the plasma level of remaining 5 proteins includ-
ing Flt3L, MCP-4, TNFRSF9, TRANCE and TWEAK was slightly
but significantly (log2FC<0.15 & FDR<0.01) increased after 14 d
in the placebo group treated only with HQ (Figure 5A, Dataset
S8, Supporting Information).
2.7. Effect of CMA on the Plasma Cytokine Levels
We analyzed the effect of CMA on plasma cytokine levels and
found that 36 proteins were significantly (FDR<0.01) different
in the CMA group on Day 14 versus Day 0. 12 of these protein
markers were significantly increased whereas 24 of these protein
markers were significantly decreased on Day 14 versus Day 0.
We observed that 14 of the 36 proteins were also significantly
(FDR<0.01) differentially expressed in the placebo group (Fig-
ure 5, Dataset S8, Supporting Information). After filtering out
the proteins based on log2FC, we found that the plasma levels of
11 proteins including, IL6, IL10, IFN-gamma, CXCL10, CCL19,
CX3CL1, CXCL11, IL-15RA, IL-17C, MCP-2 and TNF were sig-
nificantly (FDR<0.01) downregulated and the plasma level of
TRANCE and EN-RAGE was significantly (FDR<0.01) upregu-
lated in the CMA group (Figure 5 and Dataset S8, Supporting
Information).
Next, we compared the differences in the decrease of the cy-
tokine levels both in CMA and placebo groups and observed that
the magnitude of the decrease in the plasma level of downreg-
ulated cytokines was greater in the CMA group compared to
placebo group on Day 14 (Figure 6 and Dataset S8, Supporting
Information). Moreover, we found that the plasma levels of CSF-
1, IL-15RA, IL18, MCP-1 and TNF were significantly downregu-
lated in the CMA group compared to placebo group on Day 14,
whereas there was no significant difference in the plasma level
of these proteins between the groups on Day 0 (Dataset S9, Sup-
porting Information).
We investigated the association between the plasma cytokine
levels and the individual metabolic activators and found that the
plasma level of most cytokine levels were significantly inversely
correlated with the plasma level of serine (Figure 5B, Dataset S10,
Supporting Information). These results demonstrate that the ad-
ministration of CMA significantly improved cytokine levels asso-
ciated with inflammation during the recovery of the COVID-19
patients and improvement in metabolic conditions in COVID-19
patients.
2.8. Effect of CMA on Global Metabolism
We identified the significantly (FDR<0.001) different plasma
metabolites on Day 14 versus Day 0 in both CMA and placebo
groups. We found that the plasma levels of 122 metabolites were
significantly different in both CMA and placebo groups, whereas
plasma levels of 231 and 20 metabolites were specifically signif-
icantly different only in the CMA and placebo groups, respec-
tively (FDR<0.001, Dataset S4, Supporting Information). Eval-
uation of plasma metabolites that differed significantly on Day
14 versus Day 0 in each group showed that larger number of
metabolites related to amino acid (Figure 6A), lipid metabolism
(Figure S5, Supporting Information) and other metabolic path-
ways (Figure S6, Supporting Information) were altered in CMA
group compared to the placebo group (Dataset S4, Supporting
Information). By investigating the metabolites involved in amino
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acid metabolism, we found that plasma levels of 25 metabolites
were significantly different both in the CMA and placebo group,
whereas 70 and 6 were specifically significantly altered only in the
CMA and placebo group, respectively (FDR<0.001, Figure 6A,
Dataset S4, Supporting Information).
Increased plasma levels of metabolites in the kynurenine path-
way were associated with COVID-19 severity.[31] In our study, we
found that plasma levels of kynurenate and 8-methoxy kynure-
nate were significantly lower on Day 14 versus Day 0 in the
CMA group (Figure 6B, Dataset S4, Supporting Information).
The plasma level of kynurenine was significantly decreased on
Day 14 versus Day 0 both in the CMA and placebo groups. How-
ever, the magnitude of the reduction of kynurenine was signifi-
cant in the CMA versus placebo on Day 14 (Figure 6C, Datasets
S4 and S5, Supporting Information). Reduction in the plasma
level of kynurenine and kynurenate was positively correlated with
plasma serine (Dataset S6, Supporting Information). Kynure-
nine, which has a prooxidant effects, is the product of trypto-
phan degradation pathway. Its aerobic irradiation produces su-
peroxide radicals and leads to cytochrome C reduction.[32] It has
been reported that increased levels of kynurenine lead to cell
death through the reactive oxygen species (ROS) pathway in na-
ture killer (NK) cells[33] and lower blood pressure in systemic
inflammation.[34]
In our study we found that plasma levels of metabolites re-
lated to the urea cycle (3-amino-2-piperidone, N,N,N-trimethyl-
alanyl proline betaine, homoarginine, and arginine) were sig-
nificantly decreased in the CMA versus placebo group on Day
14 (Figure 6B, Dataset S4, Supporting Information). Specifically,
the plasma level of 3-amino-2-piperidone was significantly de-
creased in CMA group on Day 14 versus Day 0 (Figure 6B, Dataset
S4, Supporting Information) and inversely correlated with the
plasma level of serine (Dataset S6, Supporting Information).
Emerging evidence indicates that kidney complications in
COVID-19 patients are frequent, but the potential impact of
SARS-Cov2 on the kidney is still undetermined.[35] Recent stud-
ies showed that plasma level of N,N,N-trimethyl-5-aminovalerate
involved in lysine metabolism is an indicator of elevated urinary
albumin excretion.[36] In our study, we found that the plasma
level of N,N,N-trimethyl-5-aminovalerate was significantly in-
creased on Day 14 versus Day 0 in the placebo group while its
plasma level is significantly decreased on Day 14 versus Day 0
in the CMA group (Figure 6B, Dataset S4, Supporting Informa-
tion). Moreover, the plasma level of creatinine was only signif-
icantly decreased on Day 14 versus Day 0 in the CMA group
(Figure 6B, Dataset S4, Supporting Information). Plasma level of
both creatinine and N,N,N-trimethyl-5-aminovalerate were sig-
nificantly decreased in the CMA versus placebo group on Day 14
(Dataset S5, Supporting Information). The plasma reduction on
N,N,N-trimethyl-5-aminovalerate is significantly inversely corre-
lated with the plasma level of serine (Dataset S6, Supporting In-
formation).
Lipids play a fundamental role in multiple stages of the virus
cycle. Specific lipid species of cellular membranes (e.g., choles-
terol and sphingolipids) are not only barriers but also receptors
to infection initiation.[37] In our study, plasma level of 71 metabo-
lites involved in lipid metabolism were significantly (FDR<0.001)
different in both groups, whereas 102 and 5 were specifically sig-
nificantly changed only in the CMA and placebo groups, respec-
tively (Figure S5A, Dataset S4, Supporting Information). Plasma
level of a significant number of metabolites associated with ce-
ramides and sphingomyelins were significantly decreased on
Day 14 versus Day 0 in both CMA and placebo groups (Fig-
ure S5B, Dataset S4, Supporting Information). However, the re-
duction in the plasma level of metabolites involved in ceramides
and sphingomyelins was more dramatic in the CMA group
(Figure S5B, Dataset S4, Supporting Information). Plasma level
of metabolites associated with fatty acid metabolism (acyl car-
nitines) were significantly increased in the CMA group on Day
14 versus Day 0. In both groups, plasma levels of lysophospho-
lipid, phosphatidylcholine, and androgenic steroids were signifi-
cantly increased on Day 14 versus Day 0 (Figure S5B,C, Dataset
S4, Supporting Information). These alterations were significantly
positively correlated with carnitine and serine levels (Dataset S6,
Supporting Information).
Ketone bodies have important signaling roles in restoring al-
tered energy metabolism and redox state. In this study, we found
that the plasma level of 2R,3R-dihydroxybutyrate was signifi-
cantly decreased in the CMA group on Day 14 versus Day 0
(Figure S5B, Dataset S4, Supporting Information). We also ob-
served that plasma level of carnitine and serine also showed a
significant inverse correlation with the plasma level of 2R,3R-
dihydroxybutyrate (Dataset S6, Supporting Information). We also
found that vitamins (Tocopherol, vitamin A, and riboflavin)
and benzoate metabolism were significantly increased in both
groups, whereas the plasma level of metabolites associated with
the TCA cycle intermediate products were upregulated on Day
14 versus Day 0 in the CMA (Figure S6, Dataset S4, Supporting
Information). Overall, these results indicate that the administra-
tion of CMA effected the global metabolism of the patients.
2.9. Integrative Analysis of Clinical Variables with Proteomics and
Metabolomics Data
We have studied the associations between the significantly im-
proved (decreased) clinical parameters including AST, ALT, LDH
and TGs with the plasma level of all metabolites (Dataset S11,
Supporting Information) and all inflammation proteins (Dataset
S12, Supporting Information) and presented the 10 most signifi-
cantly correlated metabolites (Figure 7A) and inflammation pro-
teins (Figure 7B). The reduction in all four clinical parameters
was significantly correlated with the plasma level of serine and
glycine. We also found that plasma level of cysteine-glutathione
disulfide was significantly inversely correlated with the level of
AST ALT and TGs. Hence, we propose that serine is the key
metabolic activator leading to the improvement in the clinical pa-
rameters in COVID-19 patients.
Figure 4. CMA alters the global metabolism of the patients. A) The plasma level of individual metabolic activators including serine, carnitine, nicoti-
namide riboside, and cysteine as well as B) their association with the 10 most significantly correlated plasma metabolites are presented using the plasma
samples obtained from 93 patients in Phase 2 clinical trial. Asterisks indicate statistical significance based on Spearman correlation analysis. FDR value
<0.01.
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Figure 5. CMA affects the plasma level of inflammation related proteins. Association between inflammation related proteins that are significantly different
between the CMA and placebo groups on Days 0 and Day 14 using the plasma samples obtained from 93 patients in Phase 2 clinical trial. A) Heatmap
shows log2FC based alterations and clustering between significant proteins on Day 14 versus Day 0 in the CMA and placebo groups. Asterisks indicate
statistical significance based on paired Student’s t test. FDR value: < 0.01. B) Heatmap shows the correlation and clustering between the plasma level all
inflammation related proteins and plasma levels of the individual constituents of CMA (including serine, carnitine, nicotinamide riboside, and cysteine).
Asterisks indicate statistical significance based on Spearman correlation analysis. p value: < 0.05. Log2FC: log2(fold change).
We also evaluated the association of plasma proteins with
the level of AST, ALT, LDH and TG and found that CDCP1 was
positively correlated with all parameters (Figure 7B, Dataset S12,
Supporting Information). Plasma level of a set of inflamma-
tory proteins (MCP-2, CXCL10, CSF-1, IL-18R1, TNF, MCP-1,
CDCP1 and VEGFA) were significantly positively correlated
with the level of ALT and AST (Figure 7B). Interestingly, we
found that plasma levels of IL10, CCL19, CXCL9, CXCL1, OPG,
CX3CL1, PD-L1, LIF-R, IFN-gamma and TRAIL were positively
correlated and TRANCE, IL18, IL-12B, TWEAK, uPA and IL6
were inversely correlated with the level of AST, however these
proteins were not significantly correlated with the level of ALT.
On the other hand, the level of ALT was also significantly
positively correlated with HGF and negatively correlated with
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Figure 6. CMA affects the plasma level of amino acids and improves metabolic health. Plasma level of amino acids that are significantly different on
Days 14 versus Day 0 in the CMA and placebo groups using the plasma samples obtained from 93 patients in Phase 2 clinical trial. A) Venn-diagram
representing the number of identified amino acids that are significantly different on Days 14 versus Day 0 in the CMA and placebo groups. The intersection
represents amino acids that were altered in both groups. Statistical significance based on paired Student’s t test. FDR value:< 0.001. Association between
the plasma level of significantly different amino acids B) in both groups (n = 25); C) only in CMA group (n = 70), and D) only in placebo group (n = 6)
on Day 14 versus Day 0. Heatmap shows log2FC based alterations in the amino acids and asterisks indicate statistical significance based on paired
Student’s t test. FDR value: < 0.001. Log2FC, log2(fold change).
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CCL28 and SCF, which were not significantly correlated with the
level of AST. Additionally, level of TG was positively correlated
with the plasma level of TRANCE, IL-10RB, CDCP1 and HGF,
however its inverse correlation was observed with the plasma
level of CX3CL1 and SCF. We also found that hemoglobin levels
were significantly correlated with the inflammatory proteins
including EN-RAGE, DNER, IL-10RB, VEGFA, HGF, CST5 and
MCP-1 (Dataset S12, Supporting Information).
Finally, we constructed a multi-omics correlation network
based on clinical variables, proteomics, and metabolomics data
(unfiltered network). The full network can be explored via iNet-
Models (http://inetmodels.com), an open-access interactive web
platform for multiomics data visualization and database. This
network showed direct and indirect intra- and interomics func-
tional relationships of different analytes. We subsequently over-
laid the statistically altered analytes (clinical variables, metabo-
lites and proteins) to the sub-network of the individual metabolic
activators (Figure 7C). The subnetwork was built from the union
of top 15 metabolite neighbors, and all protein and clinical neigh-
bors. We identified the serine as the most connected metabolic
activator to clinical variables, metabolites, and proteins. More-
over, we performed centrality analysis of the network to identify
the most central inflammation protein markers, and found that
MCP-4, IL-18R1, HGF, CXCL10 and CSF-1 were among top 10
most-central (degree) protein nodes which all showed significant
downregulation on Day 14 versus Day 0 in the CMA group. We
found that all of them, except MCP-4, were significantly inversely
correlation with serine (Dataset S13, Supporting Information).
3. Conclusion and Discussion
Our study shows that the combination of CMA and standard ther-
apy significantly reduces the mean recovery time of ambulatory
patients with COVID-19 as compared with placebo and standard
therapy (6.6 vs 9.3 d in phase-2) and (5.7 vs 9.2 d in phase-3). Our
multiomics analysis on patients recruited in phase-2 trial is con-
sistent with the notion that CMA improves clinical outcomes in
COVID-19 by improving immune response, and regulating an-
tioxidant, amino acid and lipid metabolism. After having a pos-
itive result on the phase 2 study with 93 patients, we designed
a double-blinded placebo-controlled Phase 3 study with 304 pa-
tients. We have shown that administration of the CMA acceler-
ates the recovery of the patients independent of standard therapy.
We have also shown that the clinical parameters including ALT,
LDH, creatinine and glucose were significantly improved after
the administration of the CMA in a total of 397 patients recruited
in phase 2 and phase 3 trial. In the phase 3 trial, we also included
the patients treated with FP, and again showed that CMA accel-
erates the recovery of the patients independent of the standard
therapy. We also compared the effect of the HQ and FP in the
recovery of the patients and observed no significant differences
between the drugs used in the standard therapy.
Although COVID-19 primarily causes symptoms of respira-
tory infection, it often causes gastrointestinal and hepatic symp-
toms, including nausea/vomiting, diarrhea, and elevated levels
of liver enzymes.[1] Some studies have reported that liver defi-
ciencies correlate with worse outcomes, including longer hospi-
talization, progression to severe COVID-19, admission to the in-
tensive care unit, and death.[38–41] Mounting evidence shows that
the GSH level is insufficient to maintain and regulate the thiol
redox status of the liver in subjects with liver dysfunction.[26] De-
pleted liver GSH can be restored by administration of NAC, ser-
ine and glycine which can be synthesized through the intercon-
version of serine. Serine synthesis is downregulated in NAFLD
patients, and administration of serine enhances homocysteine
metabolism in mice and rats.[42] Two other components of CMA
including carnitine and NR, which stimulate the transfer of fatty
acids from the cytosol to mitochondria, are also depleted in liver
diseases.[43–46] Hence, we have here analyzed the effect of a mix-
ture of CMA consisting of serine, a cysteine analogue, salt form
of l-carnitine and an NAD+ precursor, administrated to COVID-
19 patients to increase the GSH level in liver and other tissues.
NAD+ is an essential metabolite in cellular energy gener-
ation and redox biology. Recently, it has been shown that the
anti-coronaviral activities of four noncanonical PARP isozyme
activities are limited by cellular NAD+ status.[47] Additionally, a
significant activation of kynurenine pathway in severe COVID-
19 population has been reported.[31] Tryptophan is an essential
amino acid that is fundamental for the biosynthesis of fun-
damental neuromodulators, namely serotonin and melatonin.
Tryptophan catabolism through kynurenine pathway is the
sole route for de novo NAD+ synthesis. In this context, CMA
significantly decreased the plasma levels of metabolites involved
in kynurenine pathway, and this reduction might play a crucial
role in restoring the metabolic balance in COVID-19 patients.
The urea cycle is essential to humans for the elimination of
nitrogen from protein metabolism. Arginine is critically impor-
tant in diverse biological roles to regulate the host immune re-
sponse and defenses.[48] Interestingly, arginine has also shown
to be a key player in the life cycle of many viruses including Her-
pesviridae and Adenoviridae.[49] In parallel, arginine depletion
treatment has shown to inhibit the viral replication and trans-
mission of HSV-1.[50] Similarly, a recent study indicated antiviral
activity of arginine-depleting enzymes in patients with hepatitis
C virus.[51] In this manner, the role of the urea cycle and related
metabolites offer targets for understanding the aspects of viral
diseases and CMA might present a treatment opportunity of viral
diseases including COVID-19, without serious adverse effects.
l-serine is generally classified as a non-essential amino acid,
however under certain circumstances, vertebrates cannot synthe-
size it in sufficient quantities to meet necessary cellular demands.
Figure 7. Integrated network analysis for revealing the effect of CMA on patients. Association between the plasma level of clinical variables including
ALT, AST, LDH, TGs, and hemoglobin with plasma level of all inflammation related proteins. Heatmap shows log2FC based alterations and clustering
between the plasma level of clinical variables including ALT, AST, LDH, TG, and hemoglobin with plasma level of A) all metabolites and B) all inflammation
related proteins. Asterisks indicate statistical significance based on paired Student’s t test. p value: < 0.05. Log2FC, log2(fold change); AST, Aspartate
aminotransferase; ALT, Alanine transaminase; LDH, Lactate dehydrogenase; TGs, Triglycerides. C) Neighbors of the metabolic activators including serine,
carnitine, nicotinamide riboside, and cysteine based on the multiomics network analysis. Only analytes that are significantly altered in CMA Day 14 versus
Day 0 are highlighted. Full networks can be found in iNetModels (http://inetmodels.com).
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For instance, a recent study showed that extracellular serine is re-
quired for optimal T cell proliferation even in abundant glucose
concentrations to support T cell effector function. Restricting di-
etary serine disturb pathogen-driven response of T cells in vivo,
without altering the entire immune cell homeostasis.[14] In an-
other study in vivo deprivation of the de novo serine synthesis
impaired LPS induction of IL-1𝛽 levels and enhanced survival in
an LPS-driven model of sepsis in mice, which reveals that serine
metabolism is fundamental for GSH synthesis to maintain IL-1𝛽
cytokine production.[21]
l-carnitine is a naturally occurring substance required in
mammalian energy metabolism. It is a carrier molecule that fa-
cilitates the transport of long-chain fatty acids across the inner
mitochondrial membrane, thereby delivering substrate for oxi-
dation and subsequent energy production. l-carnitine has been
reported to possess antioxidant and anti-inflammatory potency
and its increase might be associated with the relatively decreased
inflammatory response in the patients.[52] The results of another
study using a lamb model with increased pulmonary blood flow
showed that chronic l-carnitine treatment alleviates changes in
lung carnitine homeostasis, reduces associated oxidative stress,
and improves pulmonary mitochondrial function, NO signaling
and eventually endothelial function.[53]
As with all metabolomics studies, not every metabolite can be
captured in a single assay. In this study, we were unable to mea-
sure plasma NAD+ in the study participants. NAD+ levels in
the plasma are dynamic and are typically much lower than levels
found in the cells and tissues. Unfortunately, plasma NR is not a
surrogate marker for NAD+ status, and has an estimated half-life
of 2.7 h and a Cmax of 3 h.
[54] In a clinical kinetics study following
9 d of NR supplementation, NR levels still appeared to peak and
trough at 3 h, however NAD+ levels were consistent across time
points, having reached steady state.[54] Any correlations related to
plasma NR and the up- or down-regulation of metabolites or in-
flammatory markers is not likely reflective of actual NAD+ status
in the study participants. Future research that evaluates NAD+
levels in COVID-19 patients before and after CMA treatment, as
well as treatment with the individual co-factors separately would
provide further evidence of the role of NAD+ status on potential
correlation (and causation) to changes in the metabolome and
inflammatory markers.
In this study, patients also received HQ or FP, recommended
as standard therapy in some countries. Therefore, we could not
rule out possible drug interactions based on existing data. Un-
fortunately, due to access limitations to the patients during the
study, we were unable to sample the patients directly following
the end of HQ or FP treatment. An additional mid-point analy-
sis at 7 d may have provided additional data related to the HQ
metabolites in response to the inclusion of CMA.
Many COVID-19 patients are at risk for detrimental outcomes
due to systemic inflammatory responses referred to as a cytokine
storm, a life-threatening condition is dependent on downstream
processes that lead to oxidative stress, dysregulation of iron
homeostasis, hypercoagulability, and thrombocytopenia.[55,56]
Several studies have proposed that CMA components may
effectively inhibit the production of proinflammatory molecules
(e.g., IL-6, CCL-5, CXCL-8, and CXCL-10) and improve impaired
mitochondrial functions by reducing oxidative damage, lipid
peroxidation, and disturbed glucose tolerance.[47,57] Based on
integrative analysis, we observed that CMA may interrupt the
overactive immune response and early treatment with CMA may
reduce the risk of progression to severe respiratory distress and
lung damage.
In conclusion, we evaluated the efficacy and safety of CMA in
combination with HQ or FP therapy in patients with mild-to-
moderate COVID-19 and observed that combination therapy is
safe and beneficial in patients with mild-to-moderate COVID-19.
Our analysis showed that administration of CMA is an effective
and safe treatment for COVID-19 patients.
4. Experimental Section
Trial Design and Oversight: Patients for this randomized, open-
label, placebo-controlled, phase-2 study and randomized, double-blinded,
placebo-controlled, phase-3 study were recruited at the Umraniye Training
and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Written informed consent was obtained from all participants before the
initiation of any trial-related procedures. The safety of the participants
and the risk–benefit analysis was overseen by an independent external
data-monitoring committee. The trial was conducted in accordance with
Good Clinical Practice guidelines and the principles of the Declaration
of Helsinki. The study was approved by the ethics committee of Istan-
bul Medipol University, Istanbul, Turkey, and retrospectively registered at
https://clinicaltrials.gov/ with Clinical Trial ID: NCT04573153.
Participants: Patients were enrolled in the trial if they were over
18 years of age, had a PCR-confirmed COVID-19 test within the previous
24 h, and were in stable condition not requiring hospitalization. Chest to-
mography was done to rule out pneumonia. Patients who had a partial
oxygen saturation below 93% and required hospitalization after diagnosis
were excluded. The main characteristics of the patients are summarized in
Table S2 (Supporting Information). The inclusion, exclusion, and random-
ization criteria are described in detail in the Appendix in the Supporting
Information.
Randomization, Interventions, and Follow-up: Patients were randomly
assigned to receive CMA or placebo (3:1) and also received standard ther-
apy with HQ or FP. Patient information (patient number, date of birth,
initials) was entered into the web-based randomization system, and the
randomization codes were entered into the electronic case report form.
All clinical staff were blinded to treatment, as were the participants.
Treatment started on the day of diagnosis. Both placebo and CMA were
provided in powdered form in identical plastic bottles containing a single
dose to be dissolved in water and taken orally one dose in the morning af-
ter breakfast and one dose in the evening after dinner. Each dose of CMA
contained 3.73 g l-carnitine tartrate, 2.55 g N-acetylcysteine, 1 g nicoti-
namide riboside chloride, and 12.35 g serine. All participants also received
oral HQ or FP for 5 d. The patients were contacted by telephone daily to
assess symptoms and adverse events. All patients came for a follow-up
visit on Day 14. Further information is provided in the Appendix in the
Supporting Information.
Outcomes: The primary end point in the original protocol was to as-
sess the clinical efficacy of CMA in COVID-19 patients. For the primary
purpose, the proportion of patients who fully recovered from COVID-19,
as demonstrated by being symptom free within the 14 d of the initial diag-
nosis of COVID-19, was determined. This was amended to include self-
reporting of daily symptoms and clinical status using a binomial scale
(present/absent) via daily telephone visits by clinical staff. The secondary
aim in this study was to evaluate the safety and tolerability of CMA and
HQ or FP combination. All protocol amendments were authorized and
approved by the sponsor, the institutional review board or independent
ethics committee, and the pertinent regulatory authorities.
Number and characteristics of adverse events, serious adverse events,
and treatment discontinuation due to CMA were reported from the be-
ginning of the study to the end of the follow-up period as key safety end-
points. The changes in vital signs (systolic and diastolic blood pressures,
pulse, respiratory rate, body temperature, pulse oximetry values), baseline
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values, and the status of treatment were recorded at day 0 and 14. A com-
plete list of the end points is provided in the Appendix in the Supporting
Information.
Inflammatory Proteomics: Plasma levels of inflammatory proteins
were determined with the Olink Inflammation panel (Olink Bioscience,
Uppsala, Sweden). Briefly each sample was incubated with 92 DNA-
labeled antibody pairs (proximity probes). When an antibody pair binds to
its corresponding antigens, the corresponding DNA tails form an ampli-
con by proximity extension, which can be quantified by high-throughput,
real-time PCR. Probe solution (3 µL) was mixed with 1 µL of sample and
incubated overnight at 4 °C. Then 96 µL of extension solution containing
extension enzyme and PCR reagents for the pre-amplification step was
added, and the extension products were mixed with detection reagents
and primers and loaded on the chip for qPCR analysis with the BioMark
HD System (Fluidigm Corporation, South San Francisco, CA).To minimize
inter- and intrarun variation, the data were normalized to both an internal
control and an interplate control. Normalized data were expressed in
arbitrary units (Normalized Protein eXpression, NPX) on a log2 scale and
linearized with the formula 2NPX. A high NPX indicates a high protein
concentration. The limit of detection, determined for each of the 92
assays, was defined as three standard deviations above the negative
control (background).
Untargeted Metabolomics Analysis: Plasma samples were collected
on Days 0 and 14 for nontargeted metabolite profiling by Metabolon
(Durham, NC). The samples were prepared with an automated system
(MicroLab STAR, Hamilton Company, Reno, NV). For quality control
purposes, a recovery standard was added before the first step of the
extraction. To remove protein and dissociated small molecules bound
to protein or trapped in the precipitated protein matrix, and to recover
chemically diverse metabolites, proteins were precipitated with methanol
under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) and
centrifuged. The resulting extract was divided into four fractions: one
each for analysis by ultraperformance liquid chromatography–tandem
mass spectroscopy (UPLC-MS/MS) with positive ion-mode electrospray
ionization, UPLC-MS/MS with negative ion-mode electrospray ionization,
and gas chromatography–mass spectrometry; one fraction was reserved
as a backup.
Statistical Analysis: The primary outcome was the time to recovery, de-
fined as the time from diagnosis to the first self-report of no symptom.
The sample size for each group in phase 2 and phase 3 studies were de-
tailed in Figures 1A and 2A, respectively. Recovery curves were generated
with the Kaplan-Meier method. Hazard ratios and 95% confidence inter-
vals were calculated with the Univariate and Multivariate Cox proportional-
hazards regression model based on R package survival. The age, gender,
other treatment history, cigarette, alcohol, and HQ/FP treatment in Multi-
variate Cox regression analysis were adjusted. In phase-2 study, the HQ/FP
factor was excluded since all the patients received HQ treatment and none
of them received FP treatment.
Differences in clinical measurements, proteomics, and metabolomics
data were analyzed by t-test (paired t-test within group comparison, two-
sided and by omitting the pairs with missing values) and significant levels
are detailed in the figure legends. The correlations for multi-omics net-
works were calculated using Spearman correlation and filtered with FDR
< 0.05. The analyses were performed with the SciPy package in Python 3.7.
Centrality analysis on the network was performed using Cytoscape 3.8.2.
The script used to analyze the data can be found at https://github.com/
sysmedicine/AltayEtAll_2020_Covid_CMA
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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